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Abstract: Cardiovascular diseases are the primary cause of death in the world. Pharmacological and surgical approaches are the main
treatment options for heart disease; however, heart transplantation may be the only option for advanced heart failure patients despite its
limited nature. Recent advances enabled stem cell-based therapies to become a promising treatment approach for injured or weakened
cardiac tissue. With the identification of resident and heart-specific stem cells in early 2000, new avenues of research have been opened to
understand heart development, disease, and regeneration. In this review article, different cardiac stem cell subpopulations are classified
and defined based on the expression of various characteristic surface or intracellular proteins, including, but not limited to, C-kit, Sca-1,
Isl-1, Nkx2.5, HCN4, SIRPA, Flt-1, and KDR. Understanding cardiac stem cell biology, self-renewal, and differentiation mechanisms
holds great promise for directing these processes and utilizing these cells to repair or even build new hearts.
Key words: Stem cell, cardiac stem cells, heart disease, cardiac development

1. Introduction
Cardiovascular disease and resulting heart failure
remain the leading causes of death and disability
in the world. Pharmacological (beta-blockers, ACE
inhibitors), electrophysiological (implantable cardioverter
defibrillators, pace-makers), and surgical (coronary artery
bypass grafts, left ventricular assist devices) interventions
and devices are the main therapy options. However, for
end-stage heart failure, the only therapeutic option is
heart transplantation. Due to the limited number of organ
donors and the associated complications of the surgery,
alternative pharmacological or cell-based therapies have
been continued to be investigated. From the current search
for new therapy options, stem cell-based approaches have
gained momentum over the last decade, especially after the
identification of resident cardiac stem cells (CSC). CSCs
are tissue-specific progenitors that contribute to cardiac
tissue maintenance and repair throughout adult life.
After a cardiac injury as often seen after a myocardial
infarct (MI), due to the ischemia in the myocardium, over
a billion cardiomyocytes could be lost (Olivetti, 1997). The
heart can regenerate itself with the help of the resident
CSCs or with the contribution of recruited mesenchymal
stem cells (MSCs) to a small extent. However, given
the magnitude of myocardial damage and the constant
* Correspondence: ecagavi@medipol.edu.tr
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demand for ventricular contraction to deliver blood to
the body, a timely recovery is mostly inadequate. Thus,
delivery of CSCs or activation of CSCs within the heart by
small molecules of growth factors could represent one of
the alternative sources for cell therapies because of their
capacity to generate various cell types forming the heart.
Resident CSCs or cardiac progenitor cells arise from
a certain population of mesodermal precursors during
embryogenesis (Martin-Puig et al., 2008). Various
populations of CSCs have been identified that possess the
fundamental properties of stem cells, such as multipotency,
clonogenicity, and self-renewal capacity (Beltrami et al.,
2001). An adult heart is mainly composed of cardiomyocytes,
endothelial cells, smooth muscle cells, cardiac fibroblasts,
and pericytes. Many CSC populations have the capacity to
differentiate into cardiomyocytes, and some populations
of so-called cardiovascular progenitors can give rise to
smooth muscle cells (SMCs) and endothelial cells (ECs),
as well (Bearzi et al., 2007). Beltrami et al. (2001) detected
a Ki-67-positive cell population by immunolabeling in
4% of myocyte nuclei, suggesting proliferative cells after
myocardial infarction. This observation implicates a stem
cell population that could be activated or recruited to the
infarct zone and proliferate to repair the tissue. Although
still controversial, other reports have also proposed that
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some cardiomyocytes can renew themselves, albeit at
low levels. In support of this idea, Bergmann et al. (2009)
utilized 14C, which integrates into DNA to establish the age
of cardiomyocytes in humans, and showed that less than
50% of cardiomyocytes are exchanged during a normal
lifespan (Bergmann et al., 2009).
Although heart size, beating rate, and cardiac
physiology differ significantly among different species,
common protein families lead heart development during
embryogenesis and adulthood in mammals. Model
organisms and small and large mammals are widely used
to explore CSC biology. In combination with elaborate
bioinformatics approaches, both nuclear and cell-surface
proteins have been identified as markers for CSCs and
mature cell types in the heart. Some widely studied
markers of CSC include, but are not limited to, C-kit, Sca1, SIRPA, KDR, GATA4, HCN4, Nkx2.5, and Isl-1.
In this review, we aim to summarize mainstream
studies on various CSC populations that are verified by
independent reports, briefly explain their characterization
based on specific surface antigens or specific transcription
factors that they express (Figure; Table), and briefly explain
basic clinical applications. The classifications of cardiac
stem cells based on metabolic activity, dye exclusion, and
“or else” criteria are excluded due to space limitations and
are reviewed in other reports.
2. Cardiac stem cells
2.1. C-kit+ cells
C-kit, defined as a mast/stem cell factor protein receptor
(CD117), is one of the most widely studied cell-surface

markers that define a subpopulation of CSCs (Orlic et al.,
2001; Beltrami et al., 2003; Messina et al., 2004; Castaldo et
al., 2008). C-kit-expressing stem cells have been reported
to originate from and reside in the bone marrow niche and
are recruited to the heart after a MI (Orlic et al., 2001).
Beltrami et al. (2003) reported that C-kit+ cells were a
subpopulation CSCs and those cells were negative for
expression for hematopoietic lineage markers (Lin). Freshly
isolated C-kit+/Lin- cells from adult rat myocardium tissue
can self-renew and differentiate into cardiomyocyte, SMC,
and EC lineages but failed to spontaneously contract
in vitro. It was also shown that isolated C-kit+ cells
expressed cardiac-specific transcription factors including
NKX2.5, GATA-4, and MEF-2 in the early myocyte lineage
(Henning, 2011). C-kit+ cells were then injected into an
ischemic heart, and cardiac-derived C-kit+/Lin- cells
proliferated and regenerated myocytes, SMCs, and ECs in
vivo (Beltrami et al., 2003).
Several studies have shown that, when injected
into an ischemic rat heart, C-kit+ cells contributed
to the functional myocardium by being detected in
approximately 70% of the ventricle (Sullivan et al., 2015).
Another study demonstrated that human heart explant
cultures contained C-kit+ CSCs at a rate of about 4% and
were capable of both endocardial and cardiomyogenic
differentiation (Sandstedt et al., 2014). Moreover, infusion
of C-kit+ resident CSCs reduced the rate of apoptosis and
oxidative stress in cardiomyocytes and noncardiomyocyte
cells (Kazakov et al., 2015). The molecular mechanisms
behind C-kit+ CSCs’ survival/growth and migration were
linked to the activation of PI3K and MAPK pathways
(Vajravelu et al., 2015).

Figure. Schematic presentation of lineage commitment of stem cells towards mature cardiac cells. Characteristic marker gene
expression has been depicted under each population. aSMA: alpha-Smooth muscle actinin, cTnT: cardiac troponin T, Cx43: connexin
43, eNOS: endothelial nitric oxide synthase, FHF: first heart field, MIXL1: mix paired-like homeobox, MLC2: myosin light chain
2, PECAM-1: platelet endothelial cell adhesion molecule-1, SHF: second heart field, smMHC: smooth muscle myosin heavy chain,
SSEA: stage-specific embryonic antigen, Tie1: tyrosine kinase with immunoglobulin-like and EGF-like domains, TNNT2: troponin
T-Type 2, VE-Cadherin: vascular endothelial cadherin.
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Table. Name, tissue origin, cardiac differentiation potential, and characteristic cell surface or nuclear protein marker expression of
distinct CSC subpopulations.
Name of population

Origin of cells

Differentiation potential Markers

C-kit+/Lin- cells

Bone marrow-derived
Cardiomyocytes,
mesenchymal stem cells;
smooth muscle cells,
can be detected in heart
and endothelial cells
tissue after injury

C-kit+
LinGata4+
CD31CD45Isl-1-

Beltrami et al., 2003; Di Felice
et al., 2009

Sca-1+ cells

Hematopoietic stem
cells; can be detected in
heart tissue after injury

Sca-1+ Mef2c+
Gata4+
CD31+
CD105+

Freire et al., 2014; Valente et
al., 2014

KDR+ cells

Mesodermal precursors, Cardiomyocytes,
ESC and iPSC-derived smooth muscle cells,
cells
and endothelial cells

KDR+
C-kit+
Sca-1+
MLC2v+
cTn-I+

Kattman et al., 2006; Yang et
al, 2008

Lui et al., 2013; Nsair et al.,
2012

Cohen et al., 2007, Qyang et
al., 2007; Cagavi et al., 2014

Cardiomyocytes
(after treatment with
5’-azacytidine)

References

Flt-1+/Flt-4+ cells

ESC and iPSC-derived
cells

Cardiomyocytes,
smooth muscle cells,
and endothelial cells

Flt-1+
Flt-4+
Isl-1+
Nkx2.5+
KDR+
C-kit+

Isl-1+ cells

Second heart field
progenitors, embryonic
and adult heart

Cardiomyocytes,
smooth muscle cells,
and endothelial cells

Isl-1+
Nkx2.5Gata4+
C-kitSca-1-

Nkx2.5+ cells

First heart field
progenitors, embryonic
and adult heart

Cardiomyocytes,
smooth muscle cells,
and endothelial cells

Nkx2.5+ Gata4+ Stennard et al., 2003; Zhang
et al., 2014; Ellesøe et al.,
Tbx5+
2015
Tbx18+

Mesp1+/Mesp2+ cells

Early marker for the
Cardiomyocytes,
common hematopoietic smooth muscle cells,
and cardiac lineages
and endothelial cells

Wt1+/Tbx18+ cells

Cardiac endothelial
progenitors, embryonic
heart

Wt1+
Endocardial/endothelial Tbx18+
cells
Nkx2.5+
Isl1+

SIRPA /VCAM1 cells

ESC and iPSC-derived
cells, embryonic heart

Cardiovascular cell
lineage differentiation

Nkx2.5+
Elliot et al., 2011; Den
SIRPA+
+
+ Hartogh et al., 2015
VCAM1 CD34

HCN4+ cells

First heart field
progenitors and
sinoatrial node

Cardiomyocytes and
heart conduction
system

Gata4+ HCN4+
Isl-1Nkx2.5+
Tbx3+

+
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+

Tbx5+
Nkx2.5+

Kitajima et al., 2000; Lindsley
et al., 2008

Zhou et al., 2008; Takeichi et
al., 2013

Grant, 2009; Später et al.,
2013
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Table. (Continued).

Cardiac side population

Cardiospheres

Cardiac atrial appendage cells

Side population cells in
the heart that exclude
Hoechst 33342 dye

Atrial and ventricular
heart tissue biopsies

Human atrial
appendage

Abcg2+
Cardiomyocytes
Nkx2.5+
(when cocultured with
C-kitneonatal rat ventricular
Sca-1cardiomyocytes)

Oyama et al., 2007; Nagai et
al., 2013

Cardiomyocytes

C-kit+
Sca-1+
KDR+
CD34+
Nkx2.5+
Gata4+

Messina et al., 2004

Cardiomyocytes

ALDH+
C-kit+
CD45CD34+
KDR+

He et al., 2011; Koninckx et
al., 2013

Another study demonstrated that C-kit+ cells were
localized to the subepicardium by expression of laminin-1
and integrin alpha-6 subunits, whose coexpression
may facilitate the activation of regeneration through
the epithelial–mesenchymal transition in adult hearts
(Castaldo et al., 2008). Recently, using rodent models,
Ellison et al. (2013) showed that endogenous C-kit+ CSCs
regenerated lost cardiomyocytes after myocardial damage
and argued that these cells are necessary and sufficient
for cardiac regeneration. In order to specifically show
the contribution of C-kit+ CSCs in repair, they selectively
directed apoptosis of exogenous CSCs and showed a loss
of regeneration following selective death (Ellison et al.,
2013).
Contrary to the previous reports, Sultana et al.
demonstrated that C-kit+ cells predominantly labeled a
cardiac endothelial cell population in developing and
adult murine hearts and that resident C-kit+ population
were not capable of generating cardiomyocytes (Sultana
et al., 2015). After acute cardiac injury, they showed that
C-kit+ cells retained their endothelial cell identity and did
not become myogenic progenitors or cardiomyocytes (Di
Felice et al., 2009; Sultana et al., 2015). Collectively, the true
origin and the capacity of C-kit+ cardiac cells have been
questioned vigorously. Whether C-kit+ cells can engraft
to the myocardium and directly contribute to repair
by differentiating into cardiomyocytes or assist healing
of damaged cardiac tissue by paracrine signaling and
indirectly contribute to repair still remain controversial.
2.2. Sca-1+ cells
Stem cell antigen-1 (Sca-1)-expressing cells have
hematopoietic stem cell origin and can be readily obtained

from bone marrow (Van De Run et al., 1989). Sca-1+ cardiac
progenitors are nontumorigenic in nature and have been
shown to propagate long-term in culture, express stemness
and cardiac-specific markers, and differentiate into cardiac
cell lineages, specifically beating cardiomyocytes (Oh et
al., 2003; Matsuura et al., 2004; Wang et al., 2006, 2014).
Sca-1+/C-kit- cells from rodent hearts were shown to
induce differentiation into the cardiomyogenic lineages
in response to 5-azacytidine, a DNA methyltransferase
inhibitor, in vitro (Oh et al., 2003). Transplantation of
Sca-1+/CD31- cells into acute infarcted mouse heart
ameliorated the functional decline and improved
myocardial neovascularization with modest cardiomyocyte
regeneration (Wang et al., 2006). Another study reported
that delivery of insulin-like growth factor-1 and
hepatocyte growth factor-1 combined with Sca-1+/CD31cell populations gave positive results after transplantation
therapy in an altered hostile microenvironment following
MI (Wang et al., 2014). These data indicate that accurate
factors combined with CSCs could serve as a good
candidate approach for myocardial repair.
On the contrary, numerous recent reports challenged
whether Sca-1+ cells have authentic cardiac or MSC origin.
Houlihan et al. argued that Sca-1+ cells are a subpopulation
of MSCs based on the detected expression of PDGFRα
(Houlihan et al., 2012). Moreover, the Sca-1+/Lin- heart
subset was found to be heterogeneous and displayed a
mesenchymal profile characterized by a restricted ability
to generate cardiomyocytes in vitro and in vivo, even after
injury (Valente et al., 2014). Furthermore, reporter animal
lines and lineage-tracing experiments examining cells with
different myocardial Sca-1 expression levels demonstrated
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that Sca-1 expression was low but continuous in the
myocardium during adulthood and after injury (Freire
et al., 2014). Sca-1+ cells were claimed as a ready-to-use
CSC population for cardiac repair; however, whether
the positive effects of Sca-1+ cells on cardiac recovery
are due to incorporation and cardiac differentiation or
simply inducing neighboring cells indirectly by paracrine
signaling still remains to be shown. Nevertheless, due
to their easily accessible nature and established culture
conditions, Sca-1+ cells have been widely used in clinical
trials and transplantation experiments to investigate
engraftment, survival, adhesion, and migration capacity in
the cardiac tissue (Jha et al., 2015).
2.3. KDR+ (Flk-1+) cells
Kinase insert domain receptor (KDR) is a type III
receptor tyrosine kinase, which is also known as vascular
endothelial growth factor receptor 2 (VEGFR-2) and
fetal liver kinase-1 (Flk-1). KDR was first identified as a
protein that is specific for early embryonic hematopoietic
precursors (Kabrun et al., 1997). Later reports suggested
that Flk-1+/CXCR4+/vascular endothelial cadherincells could be cardiac-specific progenitors based on the
observation of these cells in early stages of rodent embryos
and in ES-cell differentiation cultures (Yamashita et al.,
2005). Flk-1+ cells were shown to be panmesodermal
populations as they gave rise to CSCs and mature cardiac
lineages in both the first heart field (FHF) and second heart
field (SHF) during embryonic development. To test the
cardiomyogenic potential of these cells, Brachyury+/Flk-1−
population lineages were traced and shown to generate a
Flk-1+ population that displayed robust cardiac potential
in vivo (Kattman et al., 2006).
In support of the observation that KDR-expressing cells
are CSCs, Yang et al. demonstrated that KDR+ cells isolated
from human embryonic stem cell (ESC) cultures were
capable of differentiating into cardiomyocytes, SMCs, and
ECs in vitro (Yang et al., 2008). In fact, KDR expressions
were shown to increase between days 4 and 6 of human
ESC differentiation, which mimics the developmental
stage after the establishment of the primitive-streaklike population in the embryo. In the same report, gene
expression analysis showed that cardiac-specific genes
including NKX2.5, ISL1, and TBX5 were expressed at the
highest levels in the KDRlow/C-kit- cell population (Yang
et al., 2008). These findings suggest KDR+ CSCs as a
representative of one of the earliest stages in mesoderm
specification to the cardiovascular lineages that needs to
be further verified in human embryonic development.
2.4. Flt-1+/Flt-4+ cells
Vascular endothelial growth factor receptors (VEGFR)
VEGFR-1 (Flt-1), VEGFR-2 (Flk-1), and VEGFR-3 (Flt-4)
play important roles in angiogenesis, vascular remodeling,
and cellular hypoxic response. Human and mouse Flt-
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1+ and Flt-4+ coexpressing cells have been shown to
differentiate into all three cell types of the cardiovascular
lineage in vitro (Nsair et al., 2012). In vivo evaluation of
Flt-1+/Flt-4+ CSCs transplanted into the left ventricle
showed successful engraftment and differentiation into
mature beating cardiomyocytes (Nsair et al., 2012). Gene
expression analysis of endogenous mouse Flt-1+/Flt-4+
cells found that they were able to expand in vitro and they
were demonstrated to express high levels of progenitor cell
markers such as Isl-1, Nkx2.5, Flk-1, Flt-1, Flt-4, and C-kit,
but not genes associated with differentiated cardiovascular
cells (Nsair et al., 2012). It needs to be further investigated
whether these Flt-1+/Flt-4+ cells are true CSCs or a
subpopulation of Isl-1 or Nkx2.5 CSC populations.
2.5. Isl-1+ cells
A novel population of cardiovascular progenitors
was identified based on the expression of the LIMhomeodomain transcription factor Islet-1 (Isl-1). Isl-1+
CSCs belong to the SHF progenitors during embryogenesis
and contribute to the majority of the heart including the
right atrium, right ventricle, left atria, and outflow tract,
and are also present in the adult human heart (Cai et
al., 2003; Laugwitz et al., 2005; Bu et al., 2009). Lineage
tracing experiments implied that Isl-1+ CSCs do not
contribute to the left ventricle, suggesting the contribution
of other CSC populations during heart development and
possible compartmentalization and clonality based on
CSC subpopulations (Cai et al., 2003). Both in vitro and in
vivo characterization studies revealed that Isl-1+ CSCs are
able to differentiate into the three cardiovascular lineages:
cardiomyocytes, SMCs, and ECs. Isl-1+ CSCs were also
found positive for some VEGFRs, Flt-1, and KDR (Lui et
al., 2013).
In vivo activation of β-catenin has been shown
to promote the expansion of Isl-1+ CSCs through the
regulation of fibroblast growth factor (FGF) signaling,
suggesting that the Wnt/beta-catenin signaling pathway
regulates renewal of Isl-1+ progenitors (Cohen et al., 2007;
Qyang et al., 2007). Functional cardiomyocytes can be
differentiated from Isl-1+ CSC population through bone
morphogenic protein 4 (BMP4) signal activation (Cagavi
et al., 2014). Another study showed that Notch1 signaling
also regulates self-renewal, maintenance of cardiac
progenitors, and the requirement for Notch1 activity in
cardiac differentiation (Kwon et al., 2009). Moreover, a
first clinical case study on severe heart failure conducted
with cardiac progenitors recently reported that ESCderived Isl-1+ CSCs in clinical trials for MI repair in heart
failure patients had positive outcomes in the short term
(Menasché et al., 2015).
2.6. Nkx2.5+ cells
The NKX2.5 gene encodes a homeobox-containing
transcription factor that functions in heart development
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in vertebrates and invertebrates (Turbay et al., 1996;
Durocher et al., 1997; Tanaka et al., 1999; Stennard et
al., 2003; Akazawa and Komuro, 2005). Nkx2.5 is a FHF
marker; however, its contribution to both FHF and SHF
ventricular identity and cardiac function into adulthood
has been demonstrated by several reports (Akazawa and
Komuro, 2005; Zhang et al., 2014; George et al., 2015).
Nkx2.5+ CSCs were also shown to contribute to endothelial
differentiation of the embryogenic heart (Paffett-Lugassy et
al., 2013). C-kit+ and Sca-1+ progenitor cells were found to
express Nkx2.5, implying their commitment to the cardiac
lineage (Beltrami et al., 2003; Matsuura et al., 2004).
The cardiac transcription factors NKX2.5 and GATA4
are known to cooperate and play important roles in
vertebrate heart development (Durocher et al., 1997).
NKX2.5 has been shown to interact with GATA4 and
cardiac T-box factor (TBX-5). Moreover, TBX-20 also
directly interacts with NKX2.5, GATA4, and GATA5
during heart development (Stennard et al., 2003).
Global knockout of Nkx2.5 in mice results in severe
growth retardation, perturbed cardiac morphogenesis,
and lethality at approximately embryonic day 9.5 (Tanaka
et al., 1999). Mutations in the Nkx2.5 gene are known
to cause congenital heart diseases such as familial atrial
septal defect and sudden cardiac death (Ellesøe et al.,
2015). Overexpression of Nkx2.5 can induce proper
function of the adult heart (George et al., 2015). All these
findings underline the necessary role of Nkx2.5+ CSCs
in both embryonic heart development and adult human
heart maintenance.
2.7. Mesp1+ and Mesp2+ cells
Mesoderm posterior 1 (Mesp1) is one of the earliest
known markers for common progenitors of hematopoietic
and cardiac lineages. In 1996, Saga et al. showed Mesp1
gene expression at embryonic day 6.5 in the early cardiac
mesodermal population that contributes to FHF and SHF
(Saga et al., 1996). Later studies showed Mesp genes as
essential transcription factors for precardiac mesoderm
formation in mice and humans (Lindsley et al., 2008).
Double knockout studies for Mesp1 and Mesp2 resulted in
loss of mesodermal structures (Kitajima et al., 2000). In fate
mapping analysis, the Mesp1 gene was found to contribute
almost all cardiac cell layers, including the epicardium,
endocardium, and myocardium (Kitajima et al., 2006). In
a single-cell analysis, the nascent mesodermal gene Mesp1
was found to gradually terminate as the expression of the
cardiac genes TBX-5 and Nkx2.5 increased, suggesting a
role for Mesp1 at earlier stages than the CSC population
during development (Kokkinopoulos et al., 2015).
2.8. Wt1+ and Tbx18+ cells
An epicardial progenitor population in the heart was first
described by the expression of transcription factors Tbx18
and Wilms tumor 1 homolog (Wt1) (Cai et al., 2008; Zhou

et al., 2008). These Tbx18- and Wt1-expressing progenitors
are located in the epicardium and can differentiate into fully
functional cardiomyocytes (Zeng et al., 2011). Cai et al.
(2008) also reported that Tbx18+ migrated onto the outer
surface of the heart, forming the epicardium and giving
rise to myocytes in the ventricular septum and atrial and
ventricular walls. Tbx18-expressing cardiac progenitors
are also shown to contribute to differentiation into cardiac
fibroblasts and coronary smooth muscle cells. Zhou et
al. (2008) stated that Wt1+ proepicardial cells arose from
progenitors that expressed both Nkx2.5 and Isl-1 strongly,
suggesting that these progenitors have the capability to
differentiate (Zeng et al., 2011). It is noteworthy that Tbx18
and Wt1 are shown to bidirectionally control the epicardial
to mesenchymal transition in the heart (Takeichi et al.,
2013).
2.9. SIRPA+/VCAM1+ cells
Signal-regulatory protein-alpha (SIRPA, SHPS-1, or
CD172a) and vascular cell adhesion protein-1 (VCAM-1,
CD106) are cell surface proteins and their coexpression
was shown to be enriched in human cardiac lineages
(Elliot et al., 2011). By using a transgenic human ESC cell
line in which GFP expression was reported with NKX2.5 gene expression (NKX2.5-eGFP) and bioinformatic
analysis, Elliot et al. identified the coexistence of SIRPA
and VCAM1 on purified NKX2.5-eGFP CSCs and their
progeny (Elliot et al., 2011). Further characterization of
SIRPA-VCAM1 cell populations showed cardiac troponin
T (cTnT) expressions in differentiated cardiomyocytes
that were derived from NKX2.5-eGFP cells isolated from
human ESCs (Den Hartogh et al., 2015). SIRPA was
coexpressed with cTnT, indicating that it was specifically
expressed on cardiomyocyte lineages in differentiated
populations. These studies suggested SIRPA and VCAM1
as convenient and candidate cell-surface markers for
purification of live CPCs from tissue or cultured cells. One
important consideration is to pay attention to coexpression
of SIRPA-VCAM1 and the embryonic timing, as these
markers could be expressed in differentiated cardiac cells
as well as CSCs.
2.10. HCN4+ cells
Until 2011, the isolation and purification of CSCs was
primarily based on two cell surface antigens: C-kit+
(Beltrami et al., 2003) and Sca-1+ (Matsuura et al., 2004).
Recently, a distinct CSC population was identified
by expression of hyperpolarization-activated cyclic
nucleotide-gated potassium channel 4 (HCN4), a voltagegated ion channel. HCN4 is expressed specifically in the
heart, known to be a cardiac conduction system marker,
and it was recently shown to be expressed in the early
cardiac mesoderm and determined to be a FHF marker
in mice and humans (Später et al., 2013). This channel
is mostly used as a marker for the sinoatrial node and is
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correlated with the funny current, which is responsible
for pacemaking and heart rate control. HCN4 mutations
in humans result in severe bradycardia, QT prolongation,
and torsade de pointes (Grant, 2009). HCN4 is strongly
expressed in human ESCs and cardiac progenitors at
the embryonic stage; however, HCN4 is prominently
expressed in the pacemaker region in the adult heart. This
suggests that HCN4 could be a good surface marker for
isolation of a subpopulation of embryonic CSCs; however,
HCN4 would not be good option to separate CSCs in the
adult heart.
2.11. Cardiac side population cells
Side population cells, which can be identified by their
ability to exclude Hoechst 33342 dye, can generate
cardiomyocytes in vitro and in vivo and part of this
population coexpresses C-kit and/or Sca-1 (Oyama et al.,
2007). Side population cells were first described in the
bone marrow, but they are also found in other organs,
including the heart. Thus, side population cells are not
specific to the heart (Segers and Lee, 2008), but cardiac side
population cells have the potential to migrate and home
into the injured heart, and these cells can differentiate into
cardiomyocytes, ECs, or SMCs in vivo (Oyama et al., 2007;
Nagai et al., 2013). It remains unclear whether cardiac side
population cells and Sca-1+ cells emerge from the same
population or have distinct characters.
2.12. Cardiospheres
Cardiospheres were first isolated from postnatal atrial or
ventricular human biopsies and from mouse hearts and
are described as self-adherent clusters of undifferentiated
cells expressing endothelial progenitor markers (Messina
et al., 2004). In later studies, cardiospheres were shown
to contain both primitive cells and progenitors for
three cardiac lineages; that is, they can differentiate into
cardiomyocytes, ECs, and SMCs (Barile et al., 2013).
Cardiospheres were found to express C-kit, Sca-1,
and KDR proteins and were reported to self-renew and
differentiate into cardiomyocytes through coculture with
postnatal rat cardiomyocytes (Messina et al., 2004). Smith
et al. (2007) showed that human cardiospheres expressed
C-Kit and CD105, which was the regulatory component of the
transforming growth factor-β receptor complex important
in angiogenesis and hematopoiesis. Cardiospheres were
proliferative, identified by Ki-67 expression (Smith et al.,
2007). Cardiospheres contain primitive and differentiating
cells that express cardiomyocyte proteins (Nkx2.5, GATA4
cTnI, α-sarcomeric actinin) and connexin-43 (Barile et al.,
2013).
Although obtaining human heart tissues may be difficult
and contains risks, the main advantage of cardiospheres is
that CSCs can be isolated from very small tissue samples of
human myocardium and can be expanded in vitro without
losing their differentiation capacity. Moreover, autologous
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transplantation using cardiosphere cultures from the same
patient is an alternative cell source for cell therapy.
2.13. Cardiac atrial appendage cells
Cardiac atrial appendage stem cells (CASCs) were isolated
from the human left atrial appendage. CASCs were first
identified based on the high expression of aldehyde
dehydrogenase (ALDH) as well as the presence of CD34
and absence of CD45 surface marker expression (Koninckx
et al., 2013). In vitro analysis demonstrated that CASCs
possess cardiomyogenic differentiation capacity (Koninckx
et al., 2013). Importantly, following transplantation of
CASCs to the MI zone, CASCs were shown to differentiate
into cardiomyocytes in a minipig model. When compared
with the sham control, 98% of engrafted CASCs had
differentiated into cardiomyocytes (Fanton et al., 2015).
Cells obtained from samples freshly isolated from human
atrial appendages were discovered to contain a small
population of C-kit+/Lin- cells, and also were positive for
expression of KDR and CD31 proteins. Cells were able
to differentiate into different cardiac cell lineages under
directed cardiac differentiation protocols (He et al., 2011).
Although CASCs have CSC-like properties and allow
autologous cell transplantation benefits, the requirement
of an invasive approach to acquire CASCs remains an
important consideration and limitation.
2.14. Cardiac stem cell applications
2.14.1. Clinical trials
Embryonic or adult stem cells are important cell sources
for basic research and clinical research. Over the last
decade, a large number of clinical trials have been started
in order to evaluate the therapeutic role of MSC, bone
marrow-derived stem cells, and CSCs for cardiac repair in
humans. Over 650 studies for CSCs and 3661 studies for
MI were conducted up to 2016 based on the data supplied
by the official website of the National Institute of Health
(https://clinicaltrials.gov/ct2/results/details?term=cardi
ac+stem+cell). Here we discussed several representative
trials that are either ongoing or completed.
Several CSC populations provide an option to carry out
autologous cell therapy. From those, cardiosphere-derived
cells were examined and shown to provide regenerative
effects in the CArdiosphere-Derived aUtologous stem
“CElls to reverse ventricUlar dySfunction” (CADUCEUS)
clinical trial. The CADUCEUS trial was conducted
on acute MI patients to investigate the effectiveness of
cardiosphere-derived stem cells that were obtained from
right ventricular endomyocardial biopsies and transplanted
to the same patient. After 36 days of expansion in culture,
12.5–25 million autologous cardiosphere-derived cells
were administered via intracoronary infusion between
6 and 12 weeks post-MI of 25 patients (Malliaras et al.,
2014). At the end of the this trial, there were no functional
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improvements observed in the left ventricular ejection
fraction (LVEF) of patients; however, the scar tissue was
reduced significantly compared to control patients and
regional wall thickness was improved (Malliaras et al.,
2014).
As another autologous intervention, in the “Stem Cell
Infusion in Patients with Ischemic cardiOmyopathy”
(SCIPIO) trial, right atrial appendages of 23 patients were
obtained during coronary artery bypass grafting surgery
(Yacoub and Terrovitis, 2013). After 4 weeks of the surgery,
1 × 106 C-kit+/Lin- CSCs were delivered through the
coronary artery. Four months after cell transplantation,
the majority of patients showed reduced infarct size and
an improvement in LVEF when compared to the control
group (Yacoub and Terrovitis, 2013). From 2007 to 2014,
in which years the trial was conducted, no long-term
amelioration of cardiac function was reported.
The “AutoLogous human CArdiac-Derived stem cell to
Treat Ischemic cArdiomyopathy” (ALCADIA) project is
another completed trial that was conducted between 2009
and 2015. Different from previous trials, autologous CSCs
were delivered in combination with bioengineered gelatinhydrogel scaffolds that release basic FGF. Briefly, CSCs
were collected from ischemic cardiomyopathy patients and
cultured for 4 weeks before intramyocardial injection. Six
months after transplantation, cardiac imaging indicated a
significant increase in ejection fraction and regional wall
motion as well as a reduction in infarct size (Yacoub and
Terrovitis, 2013).
A large number of clinical trials have evaluated the
safety and efficacy of stem cells that have hematopoietic
or bone marrow origin for MI or heart failure patients.
Among those, “Transplantation Of Progenitor Cells
And Regeneration Enhancement in Acute Myocardial
Infarction” (TOPCARE-AMI) investigated the effects
of intracoronary infusion of circulating stem cells
and BM-MSCs in patients who had acute MI. After
cell transplantation, 53% of the patients exhibited an
improvement of LVEF and a reduction in infarct size
(Leistner et al., 2011). In another study, the C-CURE
“Cardiopoietic stem Cell therapy in heart failURE” trial
used BM-MSCs that were exposed to a cardiogenic cocktail
containing BMP-4, bFGF, and cardiotrophin (Bartunek et
al., 2013). The so called “cardiopoietic” cells were delivered
by endomyocardial injections to patients with ischemiaoriginated heart failure. The evaluation of patients who
received cardiopoietic stem cells showed an increase in
LVEF (Bartunek et al., 2013).
From 2001 to 2009, the “Tight Glycemic Control
Increases Cardiac Stem Cells During Acute Myocardial
Infarction” phase IV trial was conducted to monitor the
regenerative myocardial effects of tight glycemic control of
patients with acute MI. Three days before coronary bypass

surgery, selected patients with various glycemic levels were
administered insulin. During surgery, myocyte precursor
cells (C-kit+/MEF2C+/GATA4+ cells) were isolated from
biopsy specimens taken from the periinfarcted area and
analyzed for oxidative stress and apoptosis parameters.
Biopsy specimens from patients in the tight glycemic
control group compared to the conventional glycemic
group demonstrated an increase in regenerative capacity
of the ischemic myocardium that was associated with
reduced senescence of myocyte precursor cells (Marfella
et al., 2012).
There are several ongoing clinical trials about CSCs
in order to evaluate their therapeutic biological effects on
heart disease patients. One example is a phase II clinical
trial testing C-kit+ CSCs alone or in combination with
MSCs named “Combination of Mesenchymal and C-kit+
Cardiac Stem Cells as Regenerative Therapy for Heart
Failure” (CONCERT-HF), which was started in 2015.
Ischemic cardiomyopathy patients are being recruited
to this trial and 15 transendocardial injections of C-kit+
CSCs alone or together with MSCs are planned to be
administered to the left ventricle of accepted participants.
Another stem cell source for cardiac repair is
human cord blood-derived stromal MSCs. Due to their
low immunogenicity and availability as an allogeneic
transplantation option, the Human Umbilical Cord
Stroma MSC in Myocardial Infarction (HUC-HEART)
trial was initiated and has started to enroll participants to
evaluate the efficacy of this cell type for cardiac repair and
remodeling in humans (Can et al., 2015).
2.14.2. Cardiac tissue and organ engineering
Tissue engineering aims to regenerate damaged cardiac
tissues by combining CSCs or mature cardiac cells
together with biomaterials and/or nanoparticles loaded
with growth factors or small molecules. Cardiac issue
engineering studies have been widely conducted with stem
cells (autologous or not) and combine them with natural
or synthetic polymers, which forms a scaffold to facilitate
cell adherence and engraftment to the cardiac tissue.
Biological polymers such as collagen, gelatin, Matrigel, and
alginate are mostly utilized for seeding cardiomyocytes
and they possess several advantages including promoting
cell adhesion, survival, and differentiation (Alcon et al.,
2012; Huyer et al., 2015). Synthetic biomaterials such as
polyglycolic acid (PGA), polylactic acid (PLA), and poly
ε-caprolactone (PCL) scaffolds are mostly preferred as they
provide appropriate dispersion, spontaneous contractility,
and suitable habitats for cardiac cells to adhere to, and
they have low toxicity (Alcon et al., 2012; Huyer et al.,
2015). On the other hand, synthetic polymers have some
disadvantages such as poor cell survival, difficulty in
manipulation, toxicity, and invoking immune reactions. As
an alternative, engineered intact cardiac cell-sheets have
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been developed in order to achieve less immunogenicity
and better biocompatibility (Haraguchi et al., 2014).
CSCs are invaluable cell sources for engineering whole
hearts. This on its own is a special topic that is reviewed
elsewhere (reviewed by Murphy and Atala, 2012). An
interesting report suggested engineering of a bioartificial
heart by decellularizing rat heart by certain chemicals and
detergents. Reseeding of the decellularized heart matrix
with CSCs and ECs resulted in the recellularization of the
heart that was contracting and drug-responsive (Ott et al.,
2008). These and other reports are preliminary studies to
build an intact heart for its possible use in the clinic for
patients who are desperately seeking heart transplantation.
3. Discussion and conclusion
The studies on CSCs aim to understand the mechanisms
behind their self-renewal and differentiation patterns. This
way, we can direct these cells in their nascent environment
or use them for cell-based therapies. The heart being a
complex organ, there is no single CSC population; rather,
various CSC subpopulations have been identified that
contribute to heart development or repair at different
stages of an organism (Figure; Table). Interestingly, not all
CSCs have the same capacity to generate the same regions
in the heart; instead, different CSC subpopulations give
rise to different and/or overlapping regions in the heart,
as summarized in the Table. Moreover, the in vitro and in
vivo potential of different CSCs may vary.
Until recently, isolation of CSCs was based on
transgenic models or the expression of CSC-associated
surface antigens, such as C-kit and Sca-1. Though these
proteins are characteristic markers for hematopoietic
lineage, recently numerous studies revealed novel markers
for CSCs such as HCN4, SIRPA, VCAM1, and Flt family
proteins, giving researchers a wide range of selection. An
important consideration is that researchers need to choose
the best CSC subpopulations for the desired study, as
differences in expression in embryonic and adult hearts (as
in HCN4+ cells) as well as differences in species-specific
expression ranges (Isl-1+ CSCs) of these factors have been
reported.
Studies on CSCs and other pluripotent or multipotent
stem cells have been conducted to compare their
regenerative potential in the heart. In one such study,
Oskouei et al. determined higher potency of CSCs
compared with BM-MSCs in cardiac repair in the
ischemic heart failure model in mice (Oskouei et al., 2012).
Furthermore, transplantation of human CSCs together
with BM-MSCs was found to reduce infarct size and
recover cardiac function after MI (Williams et al., 2013).
Interestingly, adult-derived C-kit+ CSCs were less effective
than fetal CSCs, but more potent than high-dose MSCs
as determined by engraftment and cardiac differentiation
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potential, suggestive of functional differences between
adult and embryonic CSCs (Oskouei et al., 2012).
Collectively, these and other reports underline a stronger
developmental potential for embryonic CSCs compared
to adult CSCs and the possibility of better restoration
capacity of CSCs when administered in combination with
MSCs for heart tissue repair in vivo.
In recent years, researchers have identified a novel
population of stromal cells, called cardiac telocytes,
which contribute to renewal, regeneration, and repair
of tissues (Albulescu et al., 2015). In the failing human
heart, a decreased number of telocytes was detected due
to apoptosis and extracellular matrix deformities in the
damaged area (Richter and Kostin, 2015). Interestingly,
C-kit+ cardiac telocytes were also shown to coexpress
CD34/PDGFR-α, suggesting the importance of telocytes
in vascularization of heart tissue (Li et al., 2015; Zhou et
al., 2015). Moreover, the hypoxic environment created
in the epicardial and subepicardial regions may serve as
a way to regulate CSCs via Hif-1α signaling (Kocabas et
al., 2012). To this end, after knockdown of Hif-1α, there
was an increase in cardiomyocyte and endothelial lineage
differentiation suggestive of the utilization of glycolytic
metabolism in some CSC populations (Kocabas et al.,
2012).
Recently, the B lymphoma Mo-MLV insertion region
1 (Bmi1+) population was suggested to be a novel cardiac
progenitor with substantial self-maintenance potential.
The Bmi1+ CSC population was seen to contribute to the
generation of endothelial and smooth muscle cell lineages
in vivo (Valiente-Alandi et al., 2015). This cell population
needs to be further investigated to understand its potential
as CSCs.
Isolation of CSCs from neonatal or adult hearts is an
important approach to gain access to these cells; however,
CSCs are present in minute amounts in the heart. A
solution to this problem comes from the generation of
ESC-derived or induced pluripotent stem cell (iPSC)derived CSCs that can be obtained in unlimited amounts.
Efficient differentiation protocols for ESCs are being
established to direct lineage commitment of progenitors
and be able to study different stages of cardiac development
and disease. Unless using a transgenic animal model, the
requirement for efficient cell surface markers for CSCs is
a prerequisite for isolation and purification of any CSC
population, whether from intact heart tissue or from
differentiation cultures of ESCs or iPSCs. Thus, discovery
of surface markers for CSCs (SIRPA, VCAM1, Flt-1,
Flt-4, HCN4) paved the way to purify and characterize
CSC subpopulations. Importantly, these factors can be
expressed in other adult stem cell types or mature cardiac
cells. This should alert researchers to be careful about the
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stage of cells and expression of surface markers in the
right combination when isolating CSCs from heart or
differentiation cultures.
Another current research area is the direct
differentiation of CSCs from terminally differentiated
human tissue. In 2010, fibroblasts were directly converted
to cardiomyocyte-like cells using the viral delivery of a
combination of three master transcription factors: GATA4,
MEF2C, and TBX5 (Ieda et al., 2010). One recent study
used a protein-based approach in which a combination
of QQ-reagent-modified GATA4, Hand2, Mef2c, and
Tbx5 together with BMP4, activin A, and bFGF promoted
reprogramming of human dermal fibroblasts into cardiac
progenitors. When these reprogrammed cardiac cells were

transplanted into rat hearts, functional recovery in the
damaged area was observed (Li et al., 2015).
In future studies, the true potential and implications of
different CSC populations will continue to be investigated
in basic and translational research. Combinatorial
therapies of CSCs with other progenitor populations or
gene delivery options may be developed and tested for
therapy in clinical applications, which may give hope to
patients suffering from cardiovascular disorders.
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